Virtu Financial LLC Purchases 119,407 Shares of Pfizer Inc. (NYSE:PFE)

Virtu Financial LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 230.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 171,190 shares of the biopharmaceutical company's stock after buying an additional 119,407 shares during the quarter. Virtu Financial LLC's holdings in Pfizer were worth $4,542,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. PSI Advisors LLC boosted its position in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after acquiring an additional 385 shares in the last quarter. Waddell & Associates LLC boosted its position in shares of Pfizer by 1.6% during the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock valued at $723,000 after purchasing an additional 388 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its stake in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock worth $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. raised its holdings in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 391 shares in the last quarter. Finally, Lipe & Dalton lifted its position in Pfizer by 17.7% during the fourth quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock valued at $71,000 after buying an additional 400 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.58 during trading on Tuesday, reaching $25.56. 47,484,282 shares of the company traded hands, compared to its average volume of 36,645,983. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a 50 day simple moving average of $26.15 and a 200-day simple moving average of $27.02. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a market capitalization of $144.96 billion, a PE ratio of 18.13, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. The business's quarterly revenue was up 24.7% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the subject of several research reports. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research note on Wednesday, January 8th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Bank of America restated a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.